Neel K Gupta, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gupta’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A111492 · Current
Licensed to practise in California · since 2010 · expires 2028-01-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MDRE.ML.20008617Physician And Surgeon Residency Limited License · since 2006 · expires 2008-07-31ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$123,385
Medicare paid this office $123,385 for 257 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 121 | $64,953 | $106 |
| Long return visit (40+ min) | 72 | $25,259 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $11,643 | $155 |
| Hospital discharge day management, more than 30 minutes | 73 | $9,425 | $105 |
| Return visit (30+ min) | 66 | $6,141 | $75 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 121 | $64,953 | $106 |
| Long return visit (40+ min) | 72 | $25,259 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $11,643 | $155 |
| Hospital discharge day management, more than 30 minutes | 73 | $9,425 | $105 |
| Return visit (30+ min) | 66 | $6,141 | $75 |
| New patient visit (60+ min) | 12 | $1,793 | $149 |
| Short return visit (20+ min) | 14 | $832 | $49 |
Who their Medicare patients are
257 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 10% · Women 50% · Also on Medicaid 27% · Health risk score 2.16. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 70% · Cancer 33% · Diabetes 31% · Coronary heart disease 31% · Chronic kidney disease 29% · Atrial fibrillation 26% · Depression 25% · Heart failure 23% · Dementia 16% · COPD 12% · Stroke 11%.
The office billed $425,256, Medicare allowed $157,557 and paid $123,385; for 1,115 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 257 | 1,115 | 74 | 2.16 | $425,256 | $123,385 |
| 2023 | 268 | 1,056 | 74 | 2.41 | $388,915 | $116,822 |
| 2022 | 234 | 796 | 74 | 2.28 | $271,431 | $80,218 |
| 2021 | 211 | 712 | 75 | 2.27 | $238,598 | $68,462 |
| 2020 | 253 | 1,051 | 73 | 2.53 | $360,983 | $102,220 |
| 2019 | 256 | 1,110 | 72 | 2.56 | $308,654 | $103,969 |
| 2018 | 238 | 988 | 72 | 2.25 | $262,110 | $91,919 |
| 2017 | 247 | 1,203 | 72 | 2.24 | $377,607 | $115,225 |
| 2016 | 190 | 846 | 71 | 2.06 | $278,346 | $83,092 |
| 2015 | 191 | 811 | 72 | 2.31 | $269,794 | $80,095 |
| 2014 | 80 | 452 | 70 | 2.10 | $182,689 | $43,445 |
| 2013 | 22 | 164 | 66 | 1.18 | $70,605 | $13,753 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $65,057 | $109 |
| Long return visit (40+ min) | 63 | $17,321 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $12,794 | $158 |
| Hospital discharge day management, more than 30 minutes | 85 | $10,282 | $107 |
| Return visit (30+ min) | 78 | $8,037 | $81 |
| Short return visit (20+ min) | 31 | $1,586 | $48 |
2022: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $32,329 | $93 |
| Long return visit (40+ min) | 62 | $17,509 | $124 |
| Return visit (30+ min) | 83 | $10,282 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,415 | $181 |
| Hospital discharge day management, more than 30 minutes | 54 | $5,885 | $98 |
| New patient visit (60+ min) | 14 | $2,188 | $156 |
| Short return visit (20+ min) | 45 | $2,145 | $45 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $28,023 | $93 |
| Long return visit (40+ min) | 44 | $14,067 | $124 |
| Return visit (30+ min) | 71 | $8,328 | $87 |
| Hospital discharge day management, more than 30 minutes | 53 | $5,598 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,042 | $187 |
| Short return visit (20+ min) | 71 | $4,664 | $50 |
| New patient visit (60+ min) | 15 | $2,336 | $156 |
2020: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $51,382 | $97 |
| Long return visit (40+ min) | 62 | $18,534 | $102 |
| Return visit (30+ min) | 100 | $10,619 | $66 |
| Hospital discharge day management, more than 30 minutes | 79 | $9,525 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,256 | $190 |
| New patient visit (60+ min) | 31 | $4,613 | $149 |
| Return visit (30+ min) | 14 | $799 | $57 |
2019: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $50,889 | $93 |
| Long return visit (40+ min) | 75 | $22,056 | $99 |
| Return visit (30+ min) | 110 | $12,999 | $66 |
| Hospital discharge day management, more than 30 minutes | 69 | $7,781 | $97 |
| New patient visit (60+ min) | 30 | $4,501 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,405 | $184 |
2018: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $40,350 | $94 |
| Long return visit (40+ min) | 76 | $17,714 | $92 |
| Return visit (30+ min) | 97 | $12,230 | $65 |
| Hospital discharge day management, more than 30 minutes | 69 | $9,381 | $99 |
| New patient visit (60+ min) | 48 | $6,882 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,912 | $182 |
2017: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 113 | $51,678 | $91 |
| Long return visit (40+ min) | 88 | $29,683 | $97 |
| Hospital discharge day management, more than 30 minutes | 84 | $10,243 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,854 | $171 |
| New patient visit (60+ min) | 50 | $7,516 | $150 |
| Return visit (30+ min) | 57 | $6,500 | $65 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $30,832 | $93 |
| Long return visit (40+ min) | 79 | $26,212 | $96 |
| New patient visit (60+ min) | 61 | $8,743 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,553 | $172 |
| Hospital discharge day management, more than 30 minutes | 47 | $5,154 | $97 |
| Return visit (30+ min) | 36 | $4,202 | $64 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $28,493 | $93 |
| Long return visit (40+ min) | 73 | $23,115 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,569 | $159 |
| New patient visit (60+ min) | 53 | $7,696 | $145 |
| Hospital discharge day management, more than 30 minutes | 58 | $6,882 | $97 |
| Return visit (30+ min) | 38 | $4,373 | $64 |
2014: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $20,302 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,766 | $180 |
| Hospital discharge day management, more than 30 minutes | 36 | $5,136 | $95 |
| Long return visit (40+ min) | 16 | $4,144 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,435 | $64 |
| New patient visit (60+ min) | 15 | $2,244 | $150 |
2013: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $6,187 | $90 |
| Hospital discharge day management, more than 30 minutes | 13 | $2,650 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,780 | $61 |
Medicaid work
$14,844 in 2024
Medicaid paid $14,844 for 367 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 342 | $13,810 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 25 | $1,034 |
| 2024 | 367 | 2 | 17 | $14,844 |
| 2023 | 385 | 2 | 23 | $15,177 |
| 2022 | 184 | 1 | 13 | $6,582 |
| 2020 | 97 | 2 | 13 | $3,575 |
| 2018 | 50 | 1 | 12 | $1,388 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 372 | $14,609 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $568 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 184 | $6,582 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 85 | $3,032 |
| Return visit (30+ min) | 12 | $543 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 50 | $1,388 |
Drugs they prescribed that Part D paid
$1,241,514
Pharmacies billed $1,241,514 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 210) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
152 generic and 58 brand-name prescriptions · $1,241,514 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 32 | $447,113 | $13,972 |
| Lenalidomide | 29 | $379,587 | $13,089 |
| Calquence | 16 | $246,502 | $15,406 |
| Valacyclovir | 12 | $1,090 | $91 |
| Acyclovir | 30 | $492 | $16 |
See all 6 drugs
| Brukinsa | 32 | $447,113 | $13,972 |
| Lenalidomide | 29 | $379,587 | $13,089 |
| Calquence | 16 | $246,502 | $15,406 |
| Valacyclovir | 12 | $1,090 | $91 |
| Acyclovir | 30 | $492 | $16 |
| Prednisone | 19 | $58 | $3 |
Year by year
| 2024 | 210 | 30 | 0% (0) | 28% | $1,241,514 |
| 2023 | 91 | 15 | 0% (0) | 64% | $908,426 |
| 2022 | 88 | 18 | 0% (0) | 70% | $1,095,626 |
| 2021 | 78 | 11 | 0% (0) | 68% | $899,060 |
| 2020 | 99 | 25 | None | 58% | $886,373 |
| 2019 | 150 | 31 | 0% (0) | 25% | $491,275 |
| 2018 | 67 | 19 | None | 39% | $341,628 |
| 2017 | 119 | 26 | None | 41% | $484,019 |
| 2016 | 40 | 20 | 0% (0) | 28% | $122,194 |
| 2015 | 154 | 32 | 0% (0) | 31% | $211,448 |
| 2014 | 117 | 20 | None | 15% | $6,564 |
| 2013 | 80 | 15 | None | 23% | $7,711 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Revlimid | 26 | $469,676 | $18,064 |
| Brukinsa | 16 | $251,208 | $15,700 |
| Calquence | 12 | $171,460 | $14,288 |
| Acyclovir | 12 | $194 | $16 |
2022: 1 drug
| Revlimid | 52 | $952,345 | $18,314 |
2021: 1 drug
| Revlimid | 51 | $895,263 | $17,554 |
2020: 1 drug
| Revlimid | 47 | $793,790 | $16,889 |
2019: 3 drugs
| Revlimid | 25 | $387,267 | $15,491 |
| Ondansetron | 11 | $131 | $12 |
| Prednisone | 38 | $72 | $2 |
2018: 2 drugs
| Revlimid | 11 | $152,757 | $13,887 |
| Prednisone | 13 | $47 | $4 |
2017: 3 drugs
| Revlimid | 21 | $272,996 | $13,000 |
| Neupogen | 12 | $51,038 | $4,253 |
| Prednisone | 12 | $53 | $4 |
2015: 4 drugs
| Imbruvica | 16 | $176,935 | $11,058 |
| Travasol | 17 | $3,195 | $188 |
| Famotidine | 37 | $349 | $9 |
| Prednisone | 12 | $32 | $3 |
2014: 1 drug
| Acyclovir | 22 | $311 | $14 |
2013: 2 drugs
| Acyclovir | 11 | $169 | $15 |
| Amlodipine Besylate | 11 | $61 | $6 |
Money from drug and device companies
$141 in 2025
| 2025 | 1 | 1 | None | $141 |
| 2024 | 3 | 3 | None | $309 |
| 2023 | 2 | 2 | None | $197 |
| 2022 | 3 | 7 | None | $1,470 |
| 2021 | 3 | 3 | $3,588 | $3,651 |
| 2020 | 1 | 1 | $3,000 | $3,000 |
| 2019 | 1 | 2 | $1,500 | $1,625 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Epkinly | $141 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-05-14 | Epkinly | $141 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $309
| Genmab U.S. | Epkinly | $137 | 1 payment
|
| BeiGene USA | Brukinsa | $92 | 1 payment
|
| Zimmer Biomet Holdings | Persona | $81 | 1 payment
|
2023: $197
| Zimmer Biomet Holdings | Rosa | $157 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Epkinly | $40 | 1 payment
|
2022: $1,470
| DePuy Synthes Sales | None | $1,198 | 3 payments
|
| Stryker | Mako | $179 | 3 payments
|
| Axogen | Avance Nerve Graft | $93 | 1 payment
|
2021: $3,651
| Kite Pharma | Yescarta | $1,890 | 1 payment
|
| Incyte | None | $1,698 | 1 payment
|
| Axogen | Avance Nerve Graft | $64 | 1 payment
|
2020: $3,000
| Incyte | None | $3,000 | 1 payment
|
2019: $1,625
| Seattle Genetics | Adcetris | $1,625 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Phase 2 Study of Jcar017 As Second-Line Therapy in Adult Patients With Aggressive B-Cell Nhl · 2020 | Their institution | $39,077 |
| Celgene Corporation · A Phase 2 Study of Lisocabtagene Maraleucel (Jcar0 · 2020 | Their institution | $34,853 |
| Celgene Corporation · Pilot- 2l Tne 017006 - A Phase 2 Study of Jcar017 As Second-Line Therapy in Adult Patients With Aggressive B-Cell Nhl · 2023 | Their institution | $16,533 |
| Celgene Corporation · A Phase 2 Study of Lisocabtagene Maraleucel (Jcar0 · 2021 | Their institution | $8,723 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1144330416
- Licence
- CA A111492, WA ML20008617California A111492: Current · expires 2028-01-31Washington MDRE.ML.20008617: Expired
- Trained
- University of California, Davis School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-30
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1959 Ne Pacific St, Seattle, WA, 98195